Gold bars to be exempt from tariffs, White House clarifies
In a turbulent market environment, Health Catalyst Inc. (NASDAQ:HCAT) stock has touched a new 52-week low, sinking to $3.54, with the current price at $3.58. According to InvestingPro analysis, the stock appears undervalued based on its Fair Value assessment. The healthcare data and analytics company has faced significant headwinds over the past year, with its stock price reflecting a steep decline of 45.04% from the previous year. Despite the challenges, analysts maintain a bullish outlook with price targets ranging from $5 to $16, and InvestingPro data indicates expected net income growth this year. Investors have shown concern as the company grapples with the challenges within the healthcare sector, leading to a bearish trend in its stock performance. The current price level marks a critical juncture for Health Catalyst, as market watchers and stakeholders closely monitor its strategic moves to recover from this low point. For deeper insights, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro, which covers this and 1,400+ other US stocks.
In other recent news, Health Catalyst Inc. reported its first-quarter 2025 earnings, surpassing expectations with an earnings per share (EPS) of $0.01, compared to the forecasted $0.0027. The company also exceeded revenue expectations, reporting $79.41 million against a forecast of $79.21 million. Health Catalyst’s total revenue grew by 6.3% in the quarter, with organic growth accounting for approximately 4.6%. Despite issuing lower guidance for the second quarter, Evercore ISI analyst Elizabeth Anderson increased the company’s price target to $5.00, citing potential revenue growth in the second half of 2025. Canaccord Genuity adjusted its price target for Health Catalyst to $9 from $10, maintaining a Buy rating, and highlighted the company’s strategic focus on organic growth rather than mergers and acquisitions. The company launched its Ignite platform, securing 10 new clients and expanding strategic partnerships with Microsoft (NASDAQ:MSFT) and Databricks. Additionally, Health Catalyst paid off $230 million in convertible notes, which has strengthened its balance sheet.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.